Podcast

Dr. Robert J. Hamilton on statin use in men starting ADT for prostate cancer

Author(s):

Urology Times staff

Hamilton discusses findings from a recent study published in European Urology.

“The patients who use statins had longer overall survival, longer prostate cancer-specific survival, and a trend towards longer time before they became castration resistant,” Robert J. Hamilton, MD, MPH, says in this podcast. Hamilton is an associate professor of urology at the University of Toronto.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Dr. Ramasamy discusses investigational oral testosterone treatment
Dr. Ramasamy discusses investigational oral testosterone treatment
Dr. Ramasamy discusses clinical trial of nasal testosterone gel
Dr. Ramasamy discusses clinical trial of nasal testosterone gel
Rido - stock.adobe.com
A urologist’s view on virtual medicine in men’s health
Dr. Ramasamy discusses myths about testosterone therapy
Dr. Ramasamy discusses myths about testosterone therapy
Around the Practice
AEs from Novel Hormone Therapy in Nonmetastatic Castrate Resistant Prostate Cancer
Dr. Ramasamy on 2-year follow-up data of oral testosterone capsule Jatenzo
Dr. Ramasamy on 2-year follow-up data of oral testosterone capsule Jatenzo
2-year follow-up shows Jatenzo is effective, safe in men with hypogonadism
2-year follow-up shows Jatenzo is effective, safe in men with hypogonadism
Dr. Swerdloff discusses the oral testosterone capsule Jatenzo
Dr. Swerdloff discusses the oral testosterone capsule Jatenzo
Related Content
Use of testosterone does not lead to abnormal hematocrit levels
November 27th 2023

Use of testosterone does not lead to abnormal hematocrit levels

Hannah Clarke
"The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment," says Joshua Safer, MD, FACP, FACE.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
Study highlights how DTC online platforms often fail to convey risks of testosterone therapy
December 8th 2022

Study highlights how DTC online platforms often fail to convey risks of testosterone therapy

Northwestern Medicine
“While there’s benefit in improving access, there’s also potential for harm when providers fail to follow evidence-based guidelines, or when the benefits and risks of treatment are not appropriately communicated," said Joshua A. Halpern, MD.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Novel testosterone undecanoate capsule launched in US hypogonadism market
June 9th 2022

Novel testosterone undecanoate capsule launched in US hypogonadism market

Jason M. Broderick
Testosterone undecanoate (Tlando), an oral testosterone replacement therapy, was approved in March 2022 for the treatment of men with hypogonadism.
FDA approves novel testosterone undecanoate capsule for hypogonadism
March 29th 2022

FDA approves novel testosterone undecanoate capsule for hypogonadism

Jason M. Broderick
The pivotal trial supporting approval of the oral testosterone undecanoate was Study 16-002, which included 95 hypogonadal males.
© 2025 MJH Life Sciences

All rights reserved.